# 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

> **NCT03647657** · EARLY_PHASE1 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 8 (actual)

## Conditions studied

- Thyroid Cancer, Medullary

## Interventions

- **DRUG:** 177Lu-PP-F11N
- **DRUG:** Sacuitril

## Key facts

- **NCT ID:** NCT03647657
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2021-12-14
- **Final completion:** 2021-12-14
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647657, "177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03647657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*